Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026

Kexing Biopharm's Participation in CPHI & PMEC China 2026

From June 16 to 18, 2026, Kexing Biopharm participated in the CPHI & PMEC China 2026 held at the Shanghai New International Expo Center. This event served as a significant platform for the company to showcase its extensive pipeline of self-developed innovative pharmaceuticals and over 30 products targeting international markets.

During the fair, Kexing Biopharm gained considerable attention with its featured products spanning various therapeutic areas, including oncology, autoimmune diseases, and metabolic disorders. Notable blockbuster medications such as albumin-bound paclitaxel, bevacizumab, infliximab, enzalutamide, aflibercept, liraglutide, and semaglutide drew significant interest from attendees.

Research and Development Highlights

Kexing Biopharm presented numerous innovative drug programs that have potential global impact. Among these were GB18 for cancer cachexia, GB19/GB26 aimed at systemic lupus erythematosus, GB10 focusing on ophthalmic conditions, and GB20/GB24 for autoimmune diseases. Furthermore, the clinical advancements of two phase III programs, a long-acting GC and GB05 (an interferon inhalation solution), received enthusiastic responses from the audience.

The company’s diligent development of its technology platforms and its groundbreaking innovations earned it the R&D Innovation Award. This prestigious accolade, bestowed jointly by the event's organizers and leading industry experts, recognized Kexing’s contributions based on a multi-dimensional assessment that considered R&D innovation, breakthroughs in clinical development, technological applications, and market impact. The award highlighted not only the company's achievements in industrial innovation but also provided valuable insights into future trends and developments in pharmaceutical research and development.

International Collaboration Initiatives

Engagement at CPHI & PMEC China went beyond product showcasing; Kexing Biopharm’s business development team actively participated in prominent forums and round-table discussions regarding the global expansion of the pharmaceutical sector. Participants explored current themes like the international commercialization of Chinese biopharmaceutical products, shedding light on the successes of Kexing’s platform.

The exchanges facilitated valuable insights and frameworks that will optimize the company’s internationalization strategy while capitalizing on emerging global market opportunities.

On the evening of June 15, Kexing Biopharm hosted a reception for customers and partners from various countries. This informal gathering allowed for in-depth discussions about market dynamics, collaboration opportunities, and strategic planning for the future, laying a solid foundation for mutual trust and sustainable cooperation.

CPHI provided Kexing Biopharm with a strategic platform to showcase its strengths and connect with the global pharmaceutical market. The company is committed to further expanding its global footprint and partnering with international allies to make high-quality products accessible to broader markets.

This dedication underlines Kexing Biopharm's vision of progressing 'Beyond Horizons, Forward Together.'